Citius Oncology, the oncology-focused subsidiary of Citius Pharmaceuticals, Inc., announced a registered direct offering and private placement.
The offering includes the purchase of 5,142,858 shares of common stock and unregistered warrants.
The combined effective offering price for each share and warrant is $1.75, with an exercise price of $1.84 per share.
Offering Details
5,142,858 shares of common stock and unregistered warrants were priced at $1.75 per share.
Gross Proceeds
The estimated gross proceeds from the offering are approximately $9.0 million.
Closing Date
The offering is expected to close around September 10, 2025, subject to customary closing conditions.
- The offering provides Citius Oncology with significant funding of approximately $9.0 million for its operations and development.
- The successful pricing indicates investor interest in Citius Oncology's growth potential in the oncology sector.
Overall, the pricing of the registered direct offering and private placement strengthens Citius Oncology's financial position and supports its future initiatives in developing novel targeted oncology therapies.